We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

4 hedge funds and large institutions have $469 invested in Navidea Biopharmaceuticals Inc. in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% less funds holding

Funds holding: 24 → 4 (-20)

90% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 21

100% less capital invested

Capital invested by funds: $226K → $469 (-$225K)

Holders
4
Holders Change
-20
Holders Change %
-83.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baader Bank Aktiengesellschaft
Germany
+$892
2
ASN
Advisory Services Network
Georgia
+$21

Top Sellers

Rank Fund Capital Flow
1
ACM
Allred Capital Management
Texas
-$41.9K
2
State Street
State Street
Massachusetts
-$37K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$33.1K
4
VF
Virtu Financial
New York
-$30K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$24.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baader Bank Aktiengesellschaft
Germany
$435 +$892 +10,630 New
PA
2
Parallel Advisors
California
$19 – – –
ASN
3
Advisory Services Network
Georgia
$14 +$21 +250 New
BCMLT
4
Beacon Capital Management LLC (Tennessee)
Tennessee
$1 – – –
ACM
5
Allred Capital Management
Texas
– -$41.9K -466,688 Closed
State Street
6
State Street
Massachusetts
– -$37K -412,743 Closed
Geode Capital Management
7
Geode Capital Management
Massachusetts
– -$33.1K -368,830 Closed
VF
8
Virtu Financial
New York
– -$30K -333,069 Closed
Vanguard Group
9
Vanguard Group
Pennsylvania
– -$24.8K -276,491 Closed
WAM
10
Warberg Asset Management
Illinois
– -$17.5K -194,997 Closed
UBS Group
11
UBS Group
Switzerland
– -$13.5K -149,612 Closed
BlackRock
12
BlackRock
New York
– -$10.1K -113,030 Closed
LFAS
13
Level Four Advisory Services
Texas
– -$4.98K -55,555 Closed
BFM
14
Boothbay Fund Management
New York
– -$3.59K -40,000 Closed
Northern Trust
15
Northern Trust
Illinois
– -$3.54K -39,414 Closed
TSS
16
Two Sigma Securities
New York
– -$2.83K -31,553 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– -$804 -8,937 Closed
Wells Fargo
18
Wells Fargo
California
– -$504 -5,632 Closed
Morgan Stanley
19
Morgan Stanley
New York
– -$396 -4,416 Closed
Bank of America
20
Bank of America
North Carolina
– -$143 -1,604 Closed
JP Morgan Chase
21
JP Morgan Chase
New York
– -$116 -1,300 Closed
SIS
22
Sound Income Strategies
Florida
– -$54 -599 Closed
NA
23
NewEdge Advisors
Louisiana
– -$36 -412 Closed
Group One Trading
24
Group One Trading
Illinois
– -$27 -300 Closed
KFS
25
Kelly Financial Services
Massachusetts
– -$4 -50 Closed

NAVB Hedge Fund Activity: Q4 2023 in Review

4 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2023, worth a combined $469 — down 100% from $226K a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of NAVB and 2 opened new positions — a net loss of 19 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Baader Bank Aktiengesellschaft, opening a new position worth an estimated $892. The largest seller was Allred Capital Management, exiting entirely with an estimated $41.9K sold.

  • 4 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2023, down from 24 in Q3 2023.
  • Funds reported $469 of Navidea Biopharmaceuticals Inc. stock for Q4 2023, down 100% quarter-over-quarter.
  • 2 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2023 and 21 closed out, a net change of -19 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2023 was Baader Bank Aktiengesellschaft, an estimated $892 added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q4 2023 was Allred Capital Management, an estimated $41.9K sold.

Based on aggregated 13F filings for Q4 2023.